Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hugo Barrera

Surgery Chula Vista, CA Medical Doctor

NPI 1043299100 CMS profile 273625

786 3Rd Ave, #B, Chula Vista, CA 91910

Open in the dashboard

General payments

$295,331

315 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hugo Barrera of Chula Vista, CA is reported in the CMS Open Payments database as having received $295,331 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,399 26
2024 General $51,755 45
2023 General $86,618 72
2022 General $36,207 44
2021 General $40,218 44
2020 General $35,664 39
2019 General $30,469 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hugo Barrera
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Hugo Barrera were reported at $14,399. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Hugo Barrera Surgery median Middle half National median
2019 $30,469 $253 $82–$1,521 $163
2020 $35,664 $131 $40–$706 $114
2021 $40,218 $168 $50–$904 $132
2022 $36,207 $224 $76–$1,218 $149
2023 $86,618 $253 $82–$1,255 $160
2024 $51,755 $279 $90–$1,381 $164
2025 $14,399 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $290,400 252 payments
  2. TELA Bio, Inc. $2,324 23 payments
  3. Stryker Corporation $812 5 payments
  4. Davol Inc. $747 11 payments
  5. Medtronic, Inc. $442 8 payments
  6. Covidien LP $313 4 payments
  7. Baxter Healthcare $118 5 payments
  8. Ethicon US, LLC $100 3 payments
  9. Bioptics, Inc. $25 1 payment
  10. Coloplast Corp $20 1 payment
  11. Other $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $260,137 66 payments
  2. Food and Beverage $18,851 210 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,400 8 payments
  4. Travel and Lodging $5,929 30 payments
  5. Gift $14 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $289,400 251 payments
  2. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $2,276 18 payments
  3. DA VINCI SP $1,000 1 payment
  4. SPY-PHI SYSTEM $812 5 payments
  5. Phasix Mesh $619 7 payments
  6. Signia $415 6 payments
  7. EleVision $125 1 payment
  8. PHASIX $112 3 payments
  9. FLOSEAL $79 3 payments
  10. ETHICON ENDO-SURGERY Curved Intraluminal Stapler $70 1 payment
  11. Other $302 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

101

Median for General Surgery: 59

Drug cost

$691

Median for General Surgery: $393

Branded share of claims

69.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 70 $568
Neomycin Sulfate Generic 11 $88
Tramadol Hcl Generic 20 $35

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$85,910

Medicare's payments for the services billed

Medicare patients

182

Average age 74

Services billed

526

110 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 47%
Arthritis 46%
Chronic kidney disease 34%
Heart failure 31%
Ischemic heart disease 29%
Cancer 29%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record